Industry news round-up: updates from May 2025
Explore the latest advancements in real-world data (RWD), real-world evidence (RWE) and health technology assessment (HTA) as featured on The Evidence Base during May 2025.
Canada’s Drug Agency has published a new position statement outlining potential uses, risks, and responsibilities for AI-informed evidence submissions in HTA.
OneMedNet’s regulatory-grade imaging data is now accessible through the HealthVerity Marketplace, enabling integrated RWE generation for life sciences research.
Folia Health and Inspire partner to advance real-world evidence with home-reported patient data
Folia Health and Inspire are working together to collect home-reported patient data to enhance RWE generation in complex diseases.
Canada launches national inventory of rare disease registries to advance real-world evidence
Canada’s first interactive inventory of rare disease registries is now available, offering a centralized, searchable, and regularly updated resource to support regulatory, reimbursement, and HTA decisions using RWD.
Boehringer Ingelheim is expanding its RWE strategy with Datavant to support 75 additional clinical trials and multiple new molecular entities, using secure, privacy-preserving data connectivity to enhance clinical development and launch planning.
The Journal of Comparative Effectiveness Research (JCER) is pleased to announce two important developments that reflect our continued commitment to advancing the field of healthcare research.
Caresyntax and the Jacobs Institute collaborate to expand real-world evidence in surgical innovation
Caresyntax and the Jacobs Institute have announced they are teaming up to support RWE generation and enhance medical device evaluation through surgical data integration.
UK researchers to train generative model on 57 million health records to advance disease prediction
A new pioneering AI model is being trained on de-identified health records from 57 million NHS patients in England. The world-first pilot project, called Foresight AI, aims to forecast future health risks and support a shift toward personalized, preventative care.
datma’s new AI-powered capability helps pharmaceutical and life science companies map treatment pathways, uncover care variation, and identify delays using privacy-preserving federated data analysis.
Komodo Health and Nasdaq partner to launch real-world healthcare data insights for investors
Komodo Health and Nasdaq have introduced the Nasdaq Medical Claims Insights dataset, offering hedge funds, private equity, and venture capital firms access to real-world healthcare data from over 330 million patient journeys to inform investment decisions across the US healthcare and pharmaceutical sectors.
Truveta has expanded its RWD platform to include oncology, offering access to over 7 million patient journeys across more than 100 cancer types. The data aims to support researchers with a more complete view of the cancer care continuum and facilitate evidence generation for treatment evaluation.
OMNY Health has added more than 300 new clinical assessment measures to its national RWD platform, aiming to improve disease tracking, treatment evaluation, and evidence generation across key medical specialties.
Public–private collaboration GREG set to strengthen real-world evidence use across Europe
A major new initiative is set to transform how RWE is generated and applied in regulatory and HTA decision-making across Europe. The GREG project – “Testing, improving, and co-creating Guidance and Tools for Real-World Evidence Generation and Use for Decision-Making in Europe” – will bring together 29 partners from academia and industry in a five-year collaboration supported by the Innovative Health Initiative Joint Undertaking and matched industry funding.
EMA and HMA launch 2028 plan to use AI and real-world data in EU medicines regulation
The European Medicines Agency (EMA) and Heads of Medicines Agencies (HMA) have published a joint workplan outlining how data and AI will be used to support faster, evidence-based decision-making across the EU regulatory network.
Datavant expands RWE capabilities through Aetion acquisition
Datavant, a leading health data technology company, has announced the acquisition of Aetion, a global provider of RWE solutions. The strategic move aims to deliver a fully integrated platform for generating high-quality, decision-grade evidence by combining advanced data connectivity with robust analytics.
Tempus and Boehringer Ingelheim to harness RWD and AI insights to advance cancer research
Tempus AI has announced a long-term collaboration with Boehringer Ingelheim to advance oncology drug development by applying RWD, AI, and advanced analytics to accelerate biomarker discovery, patient stratification, and therapeutic innovation.
Arcturis has announced a multi-year agreement with University College London Hospitals NHS Foundation Trust (UCLH) to expand its RWD Network, aiming to advance the development of disease-specific datasets from anonymized patient data and generate advanced insights to improve healthcare.
Premier, Inc.’s inpatient and outpatient data is now accessible through the HealthVerity Marketplace, offering expanded RWE capabilities to support decision-making across clinical development, market access, and post-approval research.
UK’s MHRA issues draft guidance on use of RWD external control arms in clinical trials
A new draft guideline from the UK Medicines and Healthcare products Regulatory Agency offers guidance for sponsors on designing clinical trials that use external control arms built from RWD, with the aim of supporting regulatory submissions.
Cortechs.ai and ALZ-NET to link AI imaging with RWD to advance Alzheimer’s care
A new collaboration between Cortechs.ai and ALZ-NET combines advanced neuroimaging technology with real-world clinical data to enhance monitoring and safety for patients receiving anti-amyloid therapies for Alzheimer’s disease.
| Register for free today to become a member of The Evidence Base and receive the latest news straight to your inbox. |